Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

被引：2
|
作者：
Dong, Renshun [1 ,2 ,3 ]
Wang, Tianci [1 ,2 ,3 ]
Dong, Wei [1 ,2 ,3 ,4 ,5 ,6 ]
Zhu, He [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Qiumeng [1 ,2 ,3 ,4 ,5 ]
Liang, Huifang [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Xiaoping [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Bixiang [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Xuewu [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China
[2] Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan 430030, Hubei, Peoples R China
[3] Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China
[4] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[5] Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[6] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 173卷
基金：
中国国家自然科学基金;
关键词：
PTPRE inhibitor; Hepatocellular carcinoma; Sorafenib; Organoid; OPEN-LABEL; PLUS; ATEZOLIZUMAB; BEVACIZUMAB; METABOLISM; MYC;
D O I：
10.1016/j.biopha.2024.116366
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.
引用
收藏
页数：11
相关论文
共 50 条
  • [31] Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma
    Giannitrapani, Lydia
    Di Gaudio, Francesca
    Cervello, Melchiorre
    Scionti, Francesca
    Ciliberto, Domenico
    Staropoli, Nicoletta
    Agapito, Giuseppe
    Cannataro, Mario
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    Seidita, Aurelio
    Soresi, Maurizio
    Affronti, Marco
    Bertino, Gaetano
    Russello, Maurizio
    Ciriminna, Rosaria
    Lino, Claudia
    Spinnato, Francesca
    Verderame, Francesco
    Augello, Giuseppa
    Arbitrio, Mariamena
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [32] Increase in IkappaB Kinase Alpha Expression Suppresses the Tumor Progression and Improves the Prognosis for Nasopharyngeal Carcinoma
    Deng, Ling
    Li, Yan
    Ai, Ping
    Xie, Yuxin
    Zhu, Hong
    Chen, Nianyong
    [J]. MOLECULAR CARCINOGENESIS, 2015, 54 (02) : 156 - 165
  • [33] NOTCH 3 INHIBITION ENHANCES THE EFFECT OF SORAFENIB IN HEPATOCELLULAR CARCINOMA
    Baglioni, Michele
    Giovannini, Catia
    Gramantieri, Laura
    Toaldo, Marco Baron
    Ventrucci, Cristiano
    D'Adamo, Stefania
    Mario, Cipone
    Chieco, Pasquale
    Bolondi, Luigi
    [J]. HEPATOLOGY, 2011, 54 : 783A - 783A
  • [34] TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB
    Abou-Alfa, G. K.
    Zhao, B.
    Capanu, M.
    Guo, P.
    Liu, F.
    Jacobs, G.
    Gansukh, B.
    Moscovici, M.
    Lentini, G.
    Schwartz, L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
  • [35] EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
    Kusakabe, Yuko
    Chiba, Tetsuhiro
    Oshima, Motohiko
    Koide, Shuhei
    Rizq, Ola
    Aoyama, Kazumasa
    Ao, Junjie
    Kaneko, Tatsuya
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maeda, Takahiro
    Saito, Tomoko
    Nakagawa, Ryo
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Ogasawara, Sadahisa
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Mikata, Rintaro
    Muroyama, Ryosuke
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Jun
    Mimura, Naoya
    Ma, Anqi
    Jin, Jian
    Zen, Yoh
    Otsuka, Masayuki
    Kaneda, Atsushi
    Iwama, Atsushi
    Kato, Naoya
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy
    Chen, Yang
    Li, Jia-Xian
    Shu, Na
    Zheng, Sui-Juan
    Ma, Min
    Zhao, Zhi-Bin
    Cao, Zhi-Ting
    Zhou, Qi
    Du, Jin-Zhi
    Wang, Jun
    [J]. BIOMATERIALS SCIENCE, 2021, 9 (07) : 2508 - 2518
  • [37] EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
    Yuko Kusakabe
    Tetsuhiro Chiba
    Motohiko Oshima
    Shuhei Koide
    Ola Rizq
    Kazumasa Aoyama
    Junjie Ao
    Tatsuya Kaneko
    Hiroaki Kanzaki
    Kengo Kanayama
    Takahiro Maeda
    Tomoko Saito
    Ryo Nakagawa
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Sadahisa Ogasawara
    Eiichiro Suzuki
    Shingo Nakamoto
    Shin Yasui
    Rintaro Mikata
    Ryosuke Muroyama
    Tatsuo Kanda
    Hitoshi Maruyama
    Jun Kato
    Naoya Mimura
    Anqi Ma
    Jian Jin
    Yoh Zen
    Masayuki Otsuka
    Atsushi Kaneda
    Atsushi Iwama
    Naoya Kato
    [J]. Scientific Reports, 11
  • [38] Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
    Yoo, Jeong-Ju
    Yu, Su Jong
    Na, Juri
    Kim, Kyungmin
    Cho, Young Youn
    Lee, Yun Bin
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Kim, Yoon Jun
    Youn, Hyewon
    Yoon, Jung-Hwan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (06)
  • [39] Inhibition of osteopontin modulates tumor-stimulated immune response and suppresses mesothelioma progression
    Psallidas, Ioannis
    Magkouta, Sophia
    Pappas, Apostolos
    Moschos, Charalampos
    Vazakidou, Maria-Eleni
    Roussos, Charis
    Stathopoulos, Georgios
    Kalomenidis, Ioannis
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [40] Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma
    Kudo, Chieko
    Miura, Masahito
    Gamoh, Makio
    Niitani, Tomohito
    Tamagawa, Hiroki
    Takahashi, Kiichi
    Ichikawa, Sonoko
    Sugiyama, Katsuo
    [J]. INTERNATIONAL CANCER CONFERENCE JOURNAL, 2015, 4 (03): : 147 - 150
12345